Jane's Koselugo (Selumetinib) Success Story

This Children's Tumor Foundation story is about Jane, a young patient who started taking Koselugo (selumetinib), a MEK-inhibitor drug that proved to shrink, then stabilize the growth of her plexiform neurofibroma tumor. Jane was one of the first pediatric patients in a clinical trial at the National Institutes of Health, and her mother Kristina shares their six-year journey from clinical trial to FDA approval! Join us in celebrating the first-ever FDA approved drug for the rare disease neurofibromatosis. To read more about Koselugo (selumetinib), including the CTF-funded research that informed this clinical trial, please go to: ctf.org/progress To enable Closed Captioning, click the CC button. What is the Children's Tumor Foundation? Children’s Tumor Foundation (CTF) began as the first grassroots organization solely dedicated to finding treatments for NF. Today, CTF is a highly recognized global nonprofit foundation, the leading force in the fight to end NF, and a model for other innovative research endeavors. Visit our website at https://www.ctf.org/ Donate today at https://www.ctf.org/ways-to-give/ Follow us on our social media platforms: Facebook -   / childrenstumor   Instagram -   / childrenstumor   Twitter -   / childrenstumor   LinkedIn -   / children's-tumor-foundation   #endnf #nf1 #nf2 #nf2swn #swn #childrenstumor #neurofibromatosis #schwannomatosis #nervetumor #tumor